87 related articles for article (PubMed ID: 11118299)
21. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
22. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin.
Siligan C; Ban J; Bachmaier R; Spahn L; Kreppel M; Schaefer KL; Poremba C; Aryee DN; Kovar H
Oncogene; 2005 Apr; 24(15):2512-24. PubMed ID: 15735734
[TBL] [Abstract][Full Text] [Related]
23. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor.
Ida K; Kobayashi S; Taki T; Hanada R; Bessho F; Yamamori S; Sugimoto T; Ohki M; Hayashi Y
Int J Cancer; 1995 Nov; 63(4):500-4. PubMed ID: 7591257
[TBL] [Abstract][Full Text] [Related]
24. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
25. Lack of matrix metalloproteinase (MMP)-1 and -3 expression in Ewing sarcoma may be due to loss of accessibility of the MMP regulatory element to the specific fusion protein in vivo.
Yabe H; Fukuma M; Urano F; Yoshida K; Kato S; Toyama Y; Hata J; Umezawa A
Biochem Biophys Res Commun; 2002 Apr; 293(1):61-71. PubMed ID: 12054564
[TBL] [Abstract][Full Text] [Related]
26. Ewing sarcoma/primitive neuroectodermal tumor of the kidney: a case report. Diagnosed by immunohistochemistry and molecular analysis.
Saxena R; Sait S; Mhawech-Fauceglia P
Ann Diagn Pathol; 2006 Dec; 10(6):363-6. PubMed ID: 17126256
[TBL] [Abstract][Full Text] [Related]
27. In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing's sarcomas and peripheral primitive neuroectodermal tumors.
Krams M; Peters J; Boeckel F; Raether A; Ambros PF; Parwaresch R; Harms D
Virchows Arch; 2000 Sep; 437(3):234-40. PubMed ID: 11037342
[TBL] [Abstract][Full Text] [Related]
28. Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study.
O'Sullivan MJ; Perlman EJ; Furman J; Humphrey PA; Dehner LP; Pfeifer JD
Hum Pathol; 2001 Oct; 32(10):1109-15. PubMed ID: 11679946
[TBL] [Abstract][Full Text] [Related]
29. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
May WA; Lessnick SL; Braun BS; Klemsz M; Lewis BC; Lunsford LB; Hromas R; Denny CT
Mol Cell Biol; 1993 Dec; 13(12):7393-8. PubMed ID: 8246959
[TBL] [Abstract][Full Text] [Related]
30. Intracranial Ewing sarcoma.
Mazur MA; Gururangan S; Bridge JA; Cummings TJ; Mukundan S; Fuchs H; Larrier N; Halperin EC
Pediatr Blood Cancer; 2005 Nov; 45(6):850-6. PubMed ID: 15929128
[TBL] [Abstract][Full Text] [Related]
31. Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1.
Ramakrishnan R; Fujimura Y; Zou JP; Liu F; Lee L; Rao VN; Reddy ES
Oncogene; 2004 Sep; 23(42):7087-94. PubMed ID: 15273724
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides.
Maksimenko A; Lambert G; Bertrand JR; Fattal E; Couvreur P; Malvy C
Ann N Y Acad Sci; 2003 Dec; 1002():72-7. PubMed ID: 14751824
[TBL] [Abstract][Full Text] [Related]
33. Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies.
Maksimenko A; Malvy C; Lambert G; Bertrand JR; Fattal E; Maccario J; Couvreur P
Pharm Res; 2003 Oct; 20(10):1565-7. PubMed ID: 14620508
[TBL] [Abstract][Full Text] [Related]
34. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities.
Mao X; Miesfeldt S; Yang H; Leiden JM; Thompson CB
J Biol Chem; 1994 Jul; 269(27):18216-22. PubMed ID: 7517940
[TBL] [Abstract][Full Text] [Related]
35. Triplex-forming oligonucleotides with unexpected affinity for a nontargeted GA repeat sequence.
Beaulieu M; Barbeau B; Rassart E
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):125-30. PubMed ID: 9149848
[TBL] [Abstract][Full Text] [Related]
36. [Growth stimulation in a Ewing sarcoma after "macrophage blockade" in athymic (nude) mice].
Torhorst J
Schweiz Med Wochenschr; 1981 Sep; 111(36):1319-21. PubMed ID: 7302536
[TBL] [Abstract][Full Text] [Related]
37. N-terminal acylation of the SV40 nuclear localization signal peptide enhances its oligonucleotide binding and membrane translocation efficiencies.
Laczkó I; Váró G; Bottka S; Bálint Z; Illyés E; Vass E; Bertrand JR; Malvy C; Hollósi M
Arch Biochem Biophys; 2006 Oct; 454(2):146-54. PubMed ID: 16987492
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.
Kelleher FC; Thomas DM
Clin Sarcoma Res; 2012 Feb; 2(1):6. PubMed ID: 22587874
[TBL] [Abstract][Full Text] [Related]
39. Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease.
Hanai K; Kurokawa T; Minakuchi Y; Maeda M; Nagahara S; Miyata T; Ochiya T; Sano A
Hum Gene Ther; 2004 Mar; 15(3):263-72. PubMed ID: 15018735
[TBL] [Abstract][Full Text] [Related]
40. [Fli1 haploinsufficiency underlies Paris-Trousseau thrombopenia].
Raslova H; Favier R; Albagli O; Vainchenker W
Med Sci (Paris); 2004 Nov; 20(11):962-4. PubMed ID: 15525489
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
